Latest filing published 17 Oct 2017 for Larimar Therapeutics, Inc., €33k.
Filing timeline
BuySaleInsider track record
Closed purchases
Based on 4 purchases whose 90-day window has closed (published at least 91 days ago), the same population our ranking model reads.
Purchases by company
Since each purchase
- +174.1%Entry US$44.88 · Close at T+365 US$123.00
- +19.5%Entry US$41.28 · Close at T+365 US$49.32
- +4.2%Entry US$42.96 · Close at T+365 US$44.76
- +9.4%Entry US$37.20 · Close at T+365 US$40.68
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Frances K. Heller: trading record in brief
This profile gathers the share dealings of Frances K. Heller across 3 companies, led by Exelixis, Inc., Bristol Myers Squibb Co and Larimar Therapeutics, Inc. Over a trading history stretching from 3 June 2009 to 13 October 2017, the count stands at 17 filings.
Both buying and selling appear: 4 purchases worth €124k, against 6 sales worth €48k. Purchases outweigh sales by €76k. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. Outside the open market, there are 2 share grants and 4 option exercises. So far in 2017, the count stands at 1 purchase and no sales.
A typical purchase (the median) is worth €32k. 1 out of 4 purchases came within 30 days of a purchase by at least one other insider of the same company. Purchases made close together by different insiders form what is called a cluster. After 4 purchases with a full 90-day history, the hit rate stands at 100% and the median 90-day move at +24.9%. This is a record of the past, not a forecast.
The record was last updated on 17 October 2017 with an open-market purchase (€33k) in Larimar Therapeutics, Inc. The median gap between a trade and its publication by SEC (Form 4) is 2 days. US insiders must file a Form 4 within two business days of a trade. A sale on its own says little: insiders also sell to pay tax, fund a purchase or diversify. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Companies and markets linked to Frances K. Heller
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
- 10,000 shares@ US$3.9026.6% of flowCommon StockSEC:0000899243-17-024381:0Canonical exit: 11 Jan 2018 (T+90)
- 10,000 shares@ US$3.2324.9% of flowCommon StockSEC:0000899243-16-036035:0Canonical exit: 19 Mar 2017 (T+90)
- 10,000 shares@ US$3.5426.6% of flowCommon StockSEC:0000899243-16-033799:0Canonical exit: 13 Feb 2017 (T+90)
- 10,000 shares@ US$2.9921.9% of flowCommon StockSEC:0000899243-16-025723:0Canonical exit: 20 Oct 2016 (T+90)
- 1,609 shares0Common Stock, $0.10 par valueSEC:0000014272-14-000142:0
- 730 shares0Common Stock, $0.10 par valueSEC:0000014272-14-000142:1
- 958 shares@ US$56.14Common Stock, $0.10 par valueSEC:0000014272-14-000142:2
- 4,451 shares0Common Stock, $0.10 par valueSEC:0000014272-13-000019:0
- 1,658 shares@ US$47.24Common Stock, $0.10 par valueSEC:0000014272-13-000019:1
- 3,125 shares0Common StockSEC:0001181431-11-030590:0
- 12,500 shares0Common StockSEC:0001181431-11-010609:0
- 1,129 shares@ US$6.19common stockSEC:0001140361-09-024750:0
- 1,400 shares@ US$6.19common stockSEC:0001140361-09-024750:1
- 1,270 shares@ US$5.00Common StockSEC:0001140361-09-014120:0
- 4,900 shares@ US$5.01Common StockSEC:0001140361-09-014120:1
- 3,257 shares@ US$5.01Common StockSEC:0001140361-09-014120:2
- 1,182 shares@ US$5.02Common StockSEC:0001140361-09-014120:3
17 of 17 declarations
